JP2011517319A - メタロプロテアーゼ１２結合タンパク質 - Google Patents

メタロプロテアーゼ１２結合タンパク質 Download PDF

Info

Publication number
JP2011517319A
JP2011517319A JP2010549830A JP2010549830A JP2011517319A JP 2011517319 A JP2011517319 A JP 2011517319A JP 2010549830 A JP2010549830 A JP 2010549830A JP 2010549830 A JP2010549830 A JP 2010549830A JP 2011517319 A JP2011517319 A JP 2011517319A
Authority
JP
Japan
Prior art keywords
mmp
protein
binding protein
binding
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010549830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011517319A5 (enExample
Inventor
レーティティア デビー，
ソニア ショーンブラット，
ホート，レネ
ニコラ フラン，
Original Assignee
ダイアックス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダイアックス コーポレーション filed Critical ダイアックス コーポレーション
Publication of JP2011517319A publication Critical patent/JP2011517319A/ja
Publication of JP2011517319A5 publication Critical patent/JP2011517319A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2010549830A 2008-03-03 2009-03-03 メタロプロテアーゼ１２結合タンパク質 Withdrawn JP2011517319A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3334808P 2008-03-03 2008-03-03
US61/033,348 2008-03-03
US12783008P 2008-05-14 2008-05-14
US61/127,830 2008-05-14
PCT/US2009/035925 WO2009111507A1 (en) 2008-03-03 2009-03-03 Metalloproteinase 12 binding proteins

Publications (2)

Publication Number Publication Date
JP2011517319A true JP2011517319A (ja) 2011-06-02
JP2011517319A5 JP2011517319A5 (enExample) 2012-04-19

Family

ID=41056352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010549830A Withdrawn JP2011517319A (ja) 2008-03-03 2009-03-03 メタロプロテアーゼ１２結合タンパク質

Country Status (6)

Country Link
US (1) US8114968B2 (enExample)
EP (1) EP2262530A4 (enExample)
JP (1) JP2011517319A (enExample)
AU (1) AU2009221915A1 (enExample)
CA (1) CA2717538A1 (enExample)
WO (1) WO2009111507A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533126A (ja) * 2012-10-05 2015-11-19 カドモン コーポレイション，リミティド ライアビリティ カンパニー ヒト抗ｖｅｇｆｒ２／ｋｄｒ抗体
JP2018105726A (ja) * 2016-12-27 2018-07-05 株式会社国際電気通信基礎技術研究所 心筋梗塞、認知症、および腫瘍からなる群から選択される一種を予防、または治療するための有効成分の候補物質のスクリーニング装置、スクリーニングプログラム、およびスクリーニング方法
WO2024090571A1 (ja) * 2022-10-28 2024-05-02 慶應義塾 Ｍｍｐ１２を指標とした免疫介在性炎症性疾患の診断、及びｍｍｐ１２阻害による免疫介在性炎症性疾患の治療用医薬

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2516320C (en) * 2003-02-18 2015-05-26 Kevin Slawin Induced activation in dendritic cells
JP2007517550A (ja) 2004-01-02 2007-07-05 アドヴァンスド カーディオヴァスキュラー システムズ， インコーポレイテッド 高比重リポ蛋白をコーティングした医療デバイス
US8691210B2 (en) * 2006-10-19 2014-04-08 David M Spencer Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof
AU2009292996B2 (en) 2008-09-22 2015-04-23 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters
JP5975983B2 (ja) * 2010-04-16 2016-08-23 ベリカム ファーマシューティカルズ， インコーポレイテッド 固形腫瘍を処置するための方法
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
US9750789B2 (en) * 2011-02-18 2017-09-05 The Trustees Of Columbia University In The City Of New York Use of matrix metalloproteinase inhibitors to treat tuberculosis
HRP20250164T1 (hr) 2011-07-22 2025-04-11 Csl Behring Gmbh Inhibitorna monoklonska antitijela protiv faktora xii/xiia i njihove uporabe
MX367743B (es) 2011-12-05 2019-09-04 Trellis Bioscience Llc Anticuerpos utiles para la inmunizacion pasiva de influenza.
US9220759B2 (en) * 2012-02-23 2015-12-29 Abbott Cardiovascular Systems Inc. Treatment of diabetic patients with a drug eluting stent and adjunctive therapy
US9220584B2 (en) 2012-03-30 2015-12-29 Abbott Cardiovascular Systems Inc. Treatment of diabetic patients with a stent and locally administered adjunctive therapy
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
IL241552B2 (en) 2013-03-14 2023-09-01 Contrafect Corp Preparation and methods based on neutralizing antibodies administered intranasally for increased therapeutic efficacy
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
EP3569253A1 (en) 2013-06-05 2019-11-20 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
TWI714869B (zh) 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
ES2900004T3 (es) 2013-08-05 2022-03-15 Immatics Biotechnologies Gmbh Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (NSCLC)
AU2015214146B2 (en) 2014-02-04 2020-09-17 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
EP3104866A4 (en) 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
AU2015244025B2 (en) 2014-04-08 2019-03-21 Boston Pharmaceuticals Inc. Binding molecules specific for IL-21 and uses thereof
AU2015312117A1 (en) 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
WO2016071758A1 (en) 2014-11-03 2016-05-12 Leiden University Medical Center T cell receptors directed against bob1 and uses thereof
CN110922481A (zh) 2015-09-24 2020-03-27 第一三共株式会社 抗garp抗体
EP3410849B1 (en) * 2016-02-05 2023-07-05 Institut Pasteur Use of inhibitors of adam12 as adjuvants in tumor therapies
PE20250933A1 (es) 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
JP7234142B2 (ja) 2017-06-02 2023-03-07 ファイザー・インク Ｆｌｔ３に特異的な抗体およびその使用
US12140526B2 (en) * 2018-02-28 2024-11-12 Juno Therapeutics, Inc. Methods for detecting particles present in a cell composition
SG11202008593PA (en) 2018-03-21 2020-10-29 Five Prime Therapeutics Inc ANTIBODIES BINDING TO VISTA AT ACIDIC pH
AU2019301120A1 (en) 2018-07-11 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
US11332546B2 (en) * 2019-05-21 2022-05-17 The Regents Of The University Of California Protease inhibitory antibodies and methods of use thereof
WO2021222595A2 (en) * 2020-04-30 2021-11-04 Virtuoso Binco, Inc. Multispecific antibodies targeting cd38 and epcam and uses thereof
WO2021229306A2 (en) * 2020-05-12 2021-11-18 Virtuoso Binco,Inc. Multispecific antibodies targeting cd38 and bcma and uses thereof
KR20230083288A (ko) * 2020-09-09 2023-06-09 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 코로나바이러스 스파이크 단백질에 대한 단일클론 항체, 및 이의 용도
WO2022266039A1 (en) * 2021-06-16 2022-12-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for monitoring and treating stroke
CN118530365B (zh) * 2024-06-18 2025-03-11 辽宁得康药业集团有限公司 特异性检测mmp12蛋白的单克隆抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9615976D0 (en) * 1996-07-30 1996-09-11 Center For Clinical & Basic Re The use of proteinase inhibitors for the prevention or reduction of bone resorption
US20020063763A1 (en) * 2000-11-29 2002-05-30 Mantell David Allen Apparatus and method for removing air bubbles from an ink jet printhead
US20030157110A1 (en) * 2002-01-07 2003-08-21 Millennium Pharmaceuticals, Inc. Methods for the treatment of metabolic disorders, including obesity and diabetes
US20030235577A1 (en) * 2002-04-08 2003-12-25 Shapiro Steven D. Methods and compositions for preventing and treating microbial infections
US20050074865A1 (en) * 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20080187508A1 (en) * 2004-09-08 2008-08-07 Boys Town National Research Hospital Treatment of Golmerular Basement Membrane Disease Involving Matrix Metalloproteinase-12
CA2606084A1 (en) * 2005-06-17 2006-12-28 Abbott Laboratories Improved method of treating degenerative spinal disorders
US20070203209A1 (en) * 2005-08-18 2007-08-30 Wilmin Bartolini Useful indole compounds
WO2007024743A2 (en) * 2005-08-19 2007-03-01 Centocor, Inc. Proteolysis resistant antibody preparations

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533126A (ja) * 2012-10-05 2015-11-19 カドモン コーポレイション，リミティド ライアビリティ カンパニー ヒト抗ｖｅｇｆｒ２／ｋｄｒ抗体
JP2018105726A (ja) * 2016-12-27 2018-07-05 株式会社国際電気通信基礎技術研究所 心筋梗塞、認知症、および腫瘍からなる群から選択される一種を予防、または治療するための有効成分の候補物質のスクリーニング装置、スクリーニングプログラム、およびスクリーニング方法
WO2024090571A1 (ja) * 2022-10-28 2024-05-02 慶應義塾 Ｍｍｐ１２を指標とした免疫介在性炎症性疾患の診断、及びｍｍｐ１２阻害による免疫介在性炎症性疾患の治療用医薬

Also Published As

Publication number Publication date
CA2717538A1 (en) 2009-09-11
WO2009111507A1 (en) 2009-09-11
AU2009221915A1 (en) 2009-09-11
US20090311183A1 (en) 2009-12-17
US8114968B2 (en) 2012-02-14
EP2262530A1 (en) 2010-12-22
EP2262530A4 (en) 2012-12-05

Similar Documents

Publication Publication Date Title
US8114968B2 (en) Metalloproteinase-12 specific monoclonal antibody
US8013125B2 (en) Metalloproteinase 9 and metalloproteinase 2 binding proteins
US8008445B2 (en) Metalloproteinase 9 binding proteins
JP2011517662A5 (enExample)
JP2011517320A5 (enExample)
JP2023159314A (ja) マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
AU2011204349C1 (en) Plasma kallikrein binding proteins
US20110135573A1 (en) Metalloproteinase 9 and metalloproteinase 2 binding proteins
US9051377B2 (en) Method for treating breast cancer using antibody binding to MMP-14
CN113271956A (zh) 基质金属蛋白酶可裂解的和丝氨酸或半胱氨酸蛋白酶可裂解的底物及其使用方法
JP2022548310A (ja) 抗ｃｄ４７抗体、活性化可能抗ｃｄ４７抗体、およびその使用方法
CN110662766A (zh) Cd147抗体、可激活cd147抗体及其制备和使用方法
WO2009097397A2 (en) Metalloproteinase binding proteins
WO2010045388A2 (en) Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
AU2019204295A1 (en) Plasma kallikrein binding proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130206

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20131218